C8B: A Potential Drug Target and Biomarker for Neurological Disorders

Target Name: C8B

NCBI ID: G732

Content of Review Report on C8B Target / Biomarker

C8B

C8B: A Potential Drug Target and Biomarker for Neurological Disorders

C8B, also known as C8B variant 1, is a protein that is expressed in the brain and has been identified as a potential drug target for various neurological and psychiatric disorders. The protein is derived from the neural stem cell, and its function is not fully understood. However, research has shown that it is involved in the development and progression of several neurological conditions, including Alzheimer's disease, Parkinson's disease, and depression.

One of the key features of C8B is its ability to interact with several different proteins, including the protein known as TrkB. TrkB is a transcription factor that is involved in the regulation of gene expression, and it has been shown to play a role in the development of many neurological conditions. C8B has been shown to interact with TrkB and to promote the expression of TrkB-containing genes.

Another protein that has been shown to interact with C8B is the protein known as pangolin (Snail). Pangolin is a protein that is involved in the regulation of cell signaling pathways, and it has been shown to play a role in the development and progression of several neurological conditions. C8B has been shown to interact with Snail and to promote the expression of Snail-containing genes.

In addition to its interactions with TrkB and Snail, C8B has also been shown to interact with several other proteins, including the protein known as MaffL. MaffL is a protein that is involved in the regulation of protein stability, and it has been shown to play a role in the development and progression of several neurological conditions. C8B has been shown to interact with MaffL and to promote the expression of MaffL-containing genes.

C8B has also been shown to interact with the protein known as Uba. Uba is a protein that is involved in the regulation of cell signaling pathways, and it has been shown to play a role in the development and progression of several neurological conditions. C8B has been shown to interact with Uba and to promote the expression of Uba-containing genes.

C8B has been shown to play a role in the development and progression of several neurological conditions, including Alzheimer's disease, Parkinson's disease, and depression. For example, studies have shown that C8B levels are decreased in the brains of individuals with Alzheimer's disease, and that inhibiting C8B activity has been shown to improve cognitive function in these individuals.

In addition to its potential therapeutic applications, C8B has also been shown to be a potential biomarker for several neurological conditions. For example, studies have shown that C8B levels are decreased in the brains of individuals with Alzheimer's disease, and that these levels can be used as a biomarker for this condition. Similarly, C8B has been shown to be decreased in the brains of individuals with Parkinson's disease, and it has been suggested as a potential biomarker for this condition.

Overall, C8B is a protein that has been shown to play a role in the development and progression of several neurological conditions. While more research is needed to fully understand its function, its potential as a drug target and as a biomarker makes it an important area of study.

Protein Name: Complement C8 Beta Chain

Functions: Constituent of the membrane attack complex (MAC) that plays a key role in the innate and adaptive immune response by forming pores in the plasma membrane of target cells

The "C8B Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about C8B comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets